Dermatology Expansion Synteract has expanded into dermatology through the Cu-Tech merger and KinderPharm acquisition, creating a strong platform for large scale dermatology trials and pediatric development programs that appeals to sponsors seeking global capabilities.

Biometrics Advantage The Clindata biomarkers acquisition strengthens data management and biometrics capabilities, enabling enhanced analytics, remote monitoring, and higher data integrity for mid to late stage studies.

Emerging Biopharma Focus As a leading full service CRO for emerging biopharma, Synteract offers deep expertise across oncology, infectious disease, vaccines, neuroscience, pediatrics and rare diseases, aligning with sponsors looking for specialized, end to end development partnerships.

Growth Backing Backed by Amulet Capital Partners with a track record of organic growth, Synteract is positioned to expand services and geography, enabling multi year outsourcing partnerships and capacity for expanding pipelines.

Global Trial Reach With a footprint across six continents and global trial experience, Synteract can manage complex multinational studies with unified execution, offering a reliable partner for sponsors seeking global site access and consistency.